Synergistic bacterial compositions and methods of production and use thereof

Patent metadata

Field	Value
Publication number	US-11389490-B2
Application number	US-202017120647-A
Country	US
Kind code	B2
Filing date	Dec 14, 2020
Priority date	Nov 23, 2012
Publication date	Jul 19, 2022
Grant date	Jul 19, 2022

Abstract

Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

First claim

What is claimed is:

1. A method of treating or preventing recurrence of Clostridium difficile ( C. difficile ) infection in a subject in need thereof, comprising administering to the subject a composition comprising a first species of isolated bacterium and a second species of isolated bacterium, wherein the first species is Clostridium innocuum and the second species is Clostridium orbiscindens , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 548.

2. The method of claim 1 , wherein the first species and the second species are capable of inhibiting C. difficile growth as measured by a CivSim assay.

3. The method of claim 2 , wherein the first species and the second species are capable of inhibiting C. difficile growth in a CivSim assay with a confidence interval of >99% (++++).

4. The method of claim 1 , wherein the first species, the second species, or both are capable of forming a spore.

5. The method of claim 1 , wherein the first species, the second species, or both are in the form of spores.

6. The method of claim 1 , wherein the composition is formulated for populating the gastrointestinal tract of the subject.

7. The method of claim 1 , wherein the first species, the second species, or both are lyophilized.

8. The method of claim 1 , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 98% identical to SEQ ID NO: 548.

9. The method of claim 1 , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 99% identical to SEQ ID NO: 548.

10. The method of claim 1 , wherein the Clostridium orbiscindens comprises the 16S rDNA sequence set forth in SEQ ID NO: 548.

11. The method of claim 1 , wherein the Clostridium innocuum comprises a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 534.

12. The method of claim 1 , wherein the Clostridium innocuum comprises a 16S rDNA sequence that is at least 98% identical to SEQ ID NO: 534.

13. The method of claim 1 , wherein the Clostridium innocuum comprises a 16S rDNA sequence that is at least 99% identical to SEQ ID NO: 534.

14. The method of claim 1 , wherein the Clostridium innocuum comprises the 16S rDNA sequence set forth in SEQ ID NO: 534.

15. The method of claim 1 , wherein the composition is formulated for oral administration.

16. The method of claim 1 , wherein the composition further comprises an enteric coating.

17. A method of treating a dysbiosis in a subject in need thereof, comprising administering to the subject a composition comprising a first species of isolated bacterium and a second species of isolated bacterium, wherein the first species is Clostridium innocuum and the second species is Clostridium orbiscindens , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 548.

18. A method of producing a bacterial composition, comprising combining a first species of isolated bacterium and a second species of isolated bacterium, wherein the first species is Clostridium innocuum and the second species is Clostridium orbiscindens , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 548.

Assignees

• Seres Therapeutics Inc

Inventors

• Henn Matthew R
• Von Maltzahn Geoffrey
• D'Onofrio Anthony Mario
• Litcofsky Kevin Daniel
• Berry David Arthur
• Cook David N
• Afeyan Noubar B
• Aunins John Grant

Classifications

• A61K35/74 Primary

  Bacteria (therapeutic use of a bacterial protein A61K38/00) · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A23L33/135

  Bacteria or derivatives thereof, e.g. probiotics · CPC title

• A23V2002/00

  Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title

• A23P10/30

  Encapsulation of particles, e.g. foodstuff additives · CPC title